Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Steuber

Showing results (41-50 of 209) with videos related to

Pageof 21
Sort By:
European Urology Open Science|June 17, 2025
Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate CancerMike Wenzel, Thomas Steuber, Carolin Siech, et al.
Urologie (Heidelberg, Germany)|October 24, 2023
[Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review]Jakob Klemm, Markus von Deimling, Margit Fisch, et al.
The Prostate|November 22, 2021
Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancerFelix Preisser, Christoph Würnschimmel, Randi M Pose, et al.
European Urology|April 25, 2006
High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy seriesJochen Walz, Markus Graefen, Felix K-H Chun, et al.
European Urology|March 21, 2006
Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomyChristian Eichelberg, Andreas Erbersdobler, Alexander Haese, et al.
European Urology Focus|July 9, 2026
Natural History of Patients Eligible for PROTEUS Diagnosed with Prostate Cancer and Treated with Radical Prostatectomy Without Perioperative Systemic TreatmentBenedikt Hoeh, Giovanni Mazzucato, Pierre Tennstedt, et al.
BJU International|December 17, 2009
Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen eraHendrik Isbarn, Manuela Wanner, Georg Salomon, et al.
European Urology Focus|April 13, 2023
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease VolumeBenedikt Hoeh, Cristina Cano Garcia, Mike Wenzel, et al.
The Journal of Urology|February 21, 2017
Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® GuidelineRaisa S Pompe, Pierre I Karakiewicz, Zhe Tian, et al.
BJU International|May 5, 2018
Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systemsRaisa S Pompe, Burkhard Beyer, Alexander Haese, et al.
Pageof 21

Showing results (41-50 of 209) with videos related to

Sort By:
Pageof 21
European Urology Open Science|June 17, 2025
Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate CancerMike Wenzel, Thomas Steuber, Carolin Siech, et al.
Urologie (Heidelberg, Germany)|October 24, 2023
[Androgen deprivation therapy and cardiovascular morbidity in prostate cancer: a narrative review]Jakob Klemm, Markus von Deimling, Margit Fisch, et al.
The Prostate|November 22, 2021
Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancerFelix Preisser, Christoph Würnschimmel, Randi M Pose, et al.
European Urology|April 25, 2006
High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy seriesJochen Walz, Markus Graefen, Felix K-H Chun, et al.
European Urology|March 21, 2006
Frozen section for the management of intraoperatively detected palpable tumor lesions during nerve-sparing scheduled radical prostatectomyChristian Eichelberg, Andreas Erbersdobler, Alexander Haese, et al.
European Urology Focus|July 9, 2026
Natural History of Patients Eligible for PROTEUS Diagnosed with Prostate Cancer and Treated with Radical Prostatectomy Without Perioperative Systemic TreatmentBenedikt Hoeh, Giovanni Mazzucato, Pierre Tennstedt, et al.
BJU International|December 17, 2009
Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen eraHendrik Isbarn, Manuela Wanner, Georg Salomon, et al.
European Urology Focus|April 13, 2023
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease VolumeBenedikt Hoeh, Cristina Cano Garcia, Mike Wenzel, et al.
The Journal of Urology|February 21, 2017
Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® GuidelineRaisa S Pompe, Pierre I Karakiewicz, Zhe Tian, et al.
BJU International|May 5, 2018
Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systemsRaisa S Pompe, Burkhard Beyer, Alexander Haese, et al.
Pageof 21